Clinical Trials Logo
  1. Home
  2. Relapse
  3. NCT05927558
  4. Details
NCT05927558 Clinical Trial

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Relapse Clinical Trial

Official title:
Salvage Treatment With Glofitamab in Patients Affected by Relapsed/Refractory Non-Hodgkin B-cell Lymphoma: a GIMEMA-FIL Study

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05927558
Other study ID # IMM0123
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 22, 2023
Est. completion date December 2025

Study information
Verified date December 2023
Source Gruppo Italiano Malattie EMatologiche dell'Adulto
Contact Paola Fazi
Phone 0670390528
Email p.fazi@gimema.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.

Description:

This is an observational multicenter study aimed at assessing the anti-lymphoma activity of glofitamab in relapsed/refractory B cell non-Hodgikin lymphoma patients treated according to the Compassionate Use Program in Italy between March 2022 and September 2023. Patients will be observed for a minimum of 12 months after the last glofitamab administration.

Recruitment information / eligibility
Status Recruiting
Enrollment 96
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients who received glofitamab according to Compassionate Use Program AG42296 2. Age > 18 years 3. Patients who received at least one dose of glofitamab between March 2022 and September 2023 in the context of the compassionate use program and who completed at least 1 year of observation after last glofitamab administration unless the patient died or was lost to follow up 4. Patients who provided their consent according to local regulation to collect their data for study purposes, dead patients or patients lost to follow up for which any attempt has been made to collect their consent, according to local regulation on data privacy Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Italy Ematologia Istituto Nazionale Tumori Milano

Sponsors (1)
Lead Sponsor Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary Rate of patients in complete response Effectiveness of glofitamab in terms of complete response 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT01956695 - Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma Phase 2
Not yet recruiting NCT05926167 - Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
Recruiting NCT03710512 - Evaluation of Early Relapse After Mandibular Lengthening Surgery
Recruiting NCT04921540 - Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA N/A
Not yet recruiting NCT03830827 - MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users Phase 4
Completed NCT05250765 - Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT. N/A
Completed NCT05915273 - Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers N/A
Active, not recruiting NCT04389879 - CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial N/A
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Completed NCT01481701 - A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Recruiting NCT04723901 - Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Not yet recruiting NCT04994626 - Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Phase 2
Recruiting NCT06292364 - Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis N/A
Enrolling by invitation NCT05591703 - Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
Active, not recruiting NCT00299923 - Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy Phase 3
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Recruiting NCT04228315 - Biomarkers of P. Vivax Relapse N/A